Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChiNing decoction is a traditional Chinese medicine (TCM) formulation developed by the Tianjin Medical University Cancer Institute and Hospital for the treatment of radiation-induced oral mucositis (radiation stomatitis) in patients with head and neck cancer. It is a multi-component botanical formulation composed of nine herbal ingredients: Rhubarb, Licorice, Mint, Scutellaria, Radix Liriopes, Red peony root, Lumbricus, Radix Scrophulariae, and Forsythia. The decoction is a modified version of the classical TCM formula Liangge San. In clinical evaluations, it has been compared against recombinant human epidermal growth factor (rhEGF) spray to assess its efficacy in reducing the severity and duration of oral mucosal injury during radiotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ChiNing decoction.